AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00938509
Drug: ibuprofen suppositories
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-10 mg/kg/day-suppositories
Trial: NCT02489461
Drug: VM-1500
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VM-1500 up to 96 weeks
Trial: NCT02489461
Drug: Antiretroviral therapy (ART)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy up to 96 weeks
Trial: NCT02425826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
Trial: NCT00836004
Drug: Clindamycin 300 mg capsule
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 300 mg
Trial: NCT00006468
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006468
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006468
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02153762
Drug: Hylatopic Plus
RxNorm normalized name: Hylatopic Plus Aurstat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Trial: NCT00834964
Drug: Effexor® 25 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 25 mg, single-dose fasting
Trial: NCT01247909
Drug: Ceftriaxone v penicillin and gentamicin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
Trial: NCT01747135
Drug: VTS-270
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00944294
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Trial: NCT00849030
Drug: Anastozole (Arimidex) placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, orally, once daily
Trial: NCT03475459
Drug: NPC-15 and/or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
Trial: NCT02065154
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02718326
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00627016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule, orally, once daily for 4 weeks
Trial: NCT02505880
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
Trial: NCT01659008
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002689
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02813200
Drug: Seretide® Diskus® 500/550 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every day during 7 days
Trial: NCT02813200
Drug: Ultibro® Breezhaler® 110/50 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every day during 7 days
Trial: NCT02813200
Drug: Spiriva® Respimat® 2,5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every day during 7 days
Trial: NCT02238444
Drug: Low Molecular Weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Trial: NCT00782769
Drug: Oxybutinyn Vaginal Ring 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00782769
Drug: Oxybutinyn Vaginal Ring 6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01218178
Drug: Saline hydration plus NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
Trial: NCT01687712
Drug: Gonal-f® RFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Trial: NCT02573155
Drug: Dose 1, AZD8871 50 μg (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT02573155
Drug: Dose 2, AZD8871 100 μg (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT02573155
Drug: Dose 3, AZD8871 300 μg (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT02573155
Drug: Dose 4, AZD8871 600 µg (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT02573155
Drug: Dose 5, AZD8871 1200 µg (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT02573155
Drug: Dose 6, AZD8871 1800 μg (Part 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT02573155
Drug: Treatment A, AZD8871 dose A (Part 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Trial: NCT00387686
Drug: rhBMP-2/CPM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02257983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
Trial: NCT02646124
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg by mouth two times a day, #20
Trial: NCT02646124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 placebo capsules
Trial: NCT01520012
Drug: YH4808 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
Trial: NCT01762852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
Trial: NCT03787498
Drug: PLX2853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01520012
Drug: YH4808 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
Trial: NCT01520012
Drug: YH4808 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
Trial: NCT01520012
Drug: YH4808 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
Trial: NCT01520012
Drug: YH4808 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
Trial: NCT00896571
Drug: Ethinylestradiol/Gestogene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Trial: NCT01250379
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (doublets not allowed)
Trial: NCT02358642
Drug: Angiotensin converting enzyme inhibitor (Lisinopril)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00574132
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Trial: NCT02358642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02270242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
Trial: NCT00841191
Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
Trial: NCT00829530
Drug: Altace® 10 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg
Trial: NCT00256230
Drug: Disulfiram (DSF)
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
Trial: NCT02335099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill twice a day for 6 months
Trial: NCT03363815
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin
Trial: NCT00121550
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02586168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01911156
Drug: Continue NA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed NA during the 72 week study period
Trial: NCT01911156
Drug: Discontinue NA Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue NA Treatment
Trial: NCT00006421
Drug: 2-Fluorodeoxyglucose
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01452802
Drug: OMM (Optimal Medical Management)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
Trial: NCT00223145
Drug: Androgen blockade
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration : 6 months
Trial: NCT00583453
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Trial: NCT00583453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery
Trial: NCT00800501
Drug: sNN0029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ICV infusion at one of three dose levels
Trial: NCT00800501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ICV infusion
Trial: NCT00941265
Drug: levodopa and benserazide
RxNorm normalized name: benserazide / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
Trial: NCT00941265
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
Trial: NCT01314716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZLI administered via nebulizer three times daily
Trial: NCT00805480
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 was administered intravenously.
Trial: NCT00805480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AIN457 was administered intravenously.
Trial: NCT00865072
Drug: GLUCOPHAGE® XR 750 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Trial: NCT04994119
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Trial: NCT01928381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind placebo capsules to match AZD5213 and pregabalin
Trial: NCT04197115
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Trial: NCT04197115
Drug: Complex B
RxNorm normalized name: Complex B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
Trial: NCT00002827
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00840866
Drug: Cefzil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Tablet
Trial: NCT02135887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6# TID with meal
Trial: NCT03589313
Drug: GLPG3067 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3067 film coated tablets provided at Day 1.
Trial: NCT01411085
Drug: Risperidone + Desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04654143
Drug: BVL-GSK098 capsule, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QD
Trial: NCT00573443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Trial: NCT01443195
Drug: Iron preparation
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation).
Trial: NCT03039426
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 75 mg intramuscular, 2 hours postoperation
Trial: NCT01564862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching capsules
Trial: NCT03809611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01240161
Drug: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will have 0-3 or more FLT-PET brain scans.
Trial: NCT02083783
Drug: TRI102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formulation containing active moiety (amphetamine)
Trial: NCT01762878
Drug: GSK2269557
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
Trial: NCT01762878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for oral inhalation once daily using DIKUS device
Trial: NCT04154735
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A medication used as chemotherapy and to suppress the immune system
Trial: NCT00004897
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004897
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00481650
Drug: Leios/Alesse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02331823
Drug: Streptomycin injectable
RxNorm normalized name: streptomycin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
Trial: NCT01693523
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth two times a day (200 mg/day).
Trial: NCT00938314
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
Trial: NCT02265874
Drug: Placebo to Habitrol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01427972
Drug: LY2623091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01440803
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
Trial: NCT01427972
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally